var title_f32_14_32992="Tacrolimus: Drug information";
var content_f32_14_32992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tacrolimus: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4778?source=see_link\">",
"       Tacrolimus (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/30/6630?source=see_link\">",
"       Tacrolimus (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9971 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32992=[""].join("\n");
var outline_f32_14_32992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4778?source=related_link\">",
"      Tacrolimus (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/30/6630?source=related_link\">",
"      Tacrolimus (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_32993="Flexible bronchoscopy";
var content_f32_14_32993=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Flexible bronchoscopy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/14/32993/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32993/contributors\" id=\"au1662\">",
"       Francis D Sheski, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/14/32993/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32993/contributors\" id=\"se747\">",
"       Praveen N Mathur, MB, BS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?32/14/32993/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32993/contributors\" id=\"de8916\">",
"       Geraldine Finlay, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/14/32993?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BRONCHOSCOPY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Flexible bronchoscopy is a procedure that allows a clinician to examine the breathing passages (airways) of the lungs (",
"     <a class=\"graphic graphic_figure graphicRef67527 \" href=\"mobipreview.htm?40/17/41237\">",
"      figure 1",
"     </a>",
"     ). Flexible bronchoscopy can be either a diagnostic procedure (to find out more about a possible problem) or a therapeutic procedure (to try to treat an existing problem or condition).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR BRONCHOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Common reasons for bronchoscopy include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Unexplained symptoms related to the chest, such as persistent cough, coughing up blood, wheezing, hoarseness, noisy breathing, or shortness of breath. The airways are examined for signs of problems and samples of tissue (biopsies) can be taken and examined for evidence of infection or cancer.",
"      </li>",
"      <li>",
"       Persistent lung collapse (atelectasis) or collapse of the small air sacs in the lungs is sometimes evaluated using bronchoscopy. This may reveal a blockage, called an obstruction, from thick mucus, a foreign body, or a tumor. If possible, the clinician removes the cause of the obstruction to open the airways. Biopsies of abnormal tissue may be taken. In some cases, small tubes, called stents, are placed to hold the obstructed airway open.",
"      </li>",
"      <li>",
"       An abnormal chest x-ray may suggest problems that require closer inspection with bronchoscopy. Examples include a \"spot\" or mass, pneumonia, or other unexplained changes on chest x-ray or computed tomography (CT) scans. In most cases, fluid samples or a biopsy are obtained to look for signs of infection, cancer, or inflammation.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PREPARATIONS FOR FLEXIBLE BRONCHOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Blood tests may be needed before the procedure to ensure that you have no problems related to blood clotting. Bleeding can sometimes occur after bronchoscopy, especially if tissue samples are taken.",
"    </p>",
"    <p>",
"     You may be asked to discontinue blood thinning medications (including aspirin, clopidogrel, and warfarin) several days prior to the procedure. It's important to understand instructions about how and when to take other medications before the procedure, and also whether smoking is permitted. In addition, it is important to mention if you have had previous allergic reactions or complications during medical or dental procedures.",
"    </p>",
"    <p>",
"     It is important not to eat or drink for at least eight hours before the procedure. Dentures or other removable devices should be removed from the mouth.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      FLEXIBLE BRONCHOSCOPY PROCEDURE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Sedation and anesthesia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bronchoscopy can be done in a special procedure suite, in an operating room, or, if needed, in another area of the hospital such as the intensive care unit. You should discuss any preferences regarding sedation in advance. In most cases, intravenous (IV) sedative medications are given before the procedure to induce drowsiness and relaxation. These medications often cause you to forget what happened during the procedure. Some clinicians also play music to create a relaxed and calm environment.",
"    </p>",
"    <p>",
"     In the procedure area, you will be connected to a pulse oximeter to monitor the blood oxygen level. Blood pressure and heart activity are also monitored.",
"    </p>",
"    <p>",
"     The back of the throat will be treated with a local anesthetic spray. This helps to prevent coughing and gagging during the procedure. However, the local anesthetic often has a bad taste. If sedatives are used, they are usually given after the throat is numbed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Bronchoscope placement",
"     </span>",
"     &nbsp;&mdash;&nbsp;During bronchoscopy, a thin tube called a bronchoscope is placed in the nose or mouth (",
"     <a class=\"graphic graphic_figure graphicRef67231 \" href=\"mobipreview.htm?27/7/27762\">",
"      figure 2",
"     </a>",
"     ). The bronchoscope has a very small camera at its tip that displays pictures on a video screen or camera. Bronchoscopy is usually done with a flexible tube (flexible bronchoscopy). However, in a small number of cases, a more rigid tube is required (rigid bronchoscopy). The information provided here is relevant to patients undergoing flexible bronchoscopy.",
"    </p>",
"    <p>",
"     The bronchoscope will be placed into either the nose or the mouth, then advanced slowly down the back of the throat, through the vocal cords and into the airways. Some people have an urge to cough or feel a sensation of wanting to catch their breath. If there is significant discomfort, more anesthesia can be given.",
"    </p>",
"    <p>",
"     Once the bronchoscope has passed between the vocal cords, it is difficult to speak normally. This can be frightening, but it is expected and resolves when the bronchoscope is removed. Oxygen levels are monitored at all times to be sure you are getting enough air.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are partially alert during the procedure, you can listen as the doctor explains what is happening at each stage.",
"    </p>",
"    <p>",
"     In some cases, samples of tissue and fluid are taken using devices passed through the bronchoscope. Other instruments can be used to remove foreign objects, secretions, abnormal growths, to place an airway stent, or to deliver radiation therapy directly to the abnormal area. During these procedures, the doctor may ask you if you have pain in the chest, back, or shoulders. In general, you should not feel pain. You may also be asked to hold your breath for short periods of time during parts of the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      FLEXIBLE BRONCHOSCOPY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Bronchoscopy is a safe procedure. Complications are infrequent and usually minor. One study of more than 4000 flexible bronchoscopies performed at a university hospital showed that complications occurred in only 1.3 percent of cases. Complications may be related to the procedure itself or to adverse reactions caused by sedatives or numbing medicines.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bleeding can occur, especially if a biopsy is taken during the procedure. Bleeding is more likely if the airway was inflamed or damaged by disease. Usually, bleeding is minor and stops without treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Fever and infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fever is relatively common after bronchoscopy but is not always a sign of infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Myocardial ischemia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Myocardial ischemia refers to a strain on the heart muscle caused by insufficient blood flow to the coronary arteries. A heart attack, or myocardial infarction, is an extreme form of myocardial ischemia that results in damage to the heart. Certain patients may be at risk for myocardial ischemia following bronchoscopy, including those with cardiac disease. Many doctors recommend delaying bronchoscopy for six weeks after a heart attack, if possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Reduced oxygen",
"     </span>",
"     &nbsp;&mdash;&nbsp;The oxygen level in the patient's blood is monitored continuously during bronchoscopy using a small probe on the finger. The level of oxygen in the blood may fall briefly during the procedure. This drop is usually mild, and the level usually returns to normal without treatment. Extra oxygen may be given to maintain a safe level of oxygen in the blood.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Lung leak or collapse",
"     </span>",
"     &nbsp;&mdash;&nbsp;In rare cases, the airway may be injured during bronchoscopy, particularly if the lung is significantly inflamed or diseased. If the lung is punctured, it can cause an air leak (pneumothorax), which results in lung collapse. This complication is more likely if a biopsy is taken during the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      CARE FOLLOWING FLEXIBLE BRONCHOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     You will be monitored closely for two to four hours after bronchoscopy. Eating and drinking is not allowed until the effects of the anesthesia have worn off and you have a normal gag reflex. Some doctors routinely perform a chest x-ray after performing a biopsy to check for signs of a pneumothorax.",
"    </p>",
"    <p>",
"     If you return home on the day of the procedure, you must not drive an automobile or operate heavy machinery, because of the lingering effects of sedation. A family member or friend must be available to drive or accompany you home.",
"    </p>",
"    <p>",
"     Once at home, you may have a mild sore throat, hoarseness, cough, or muscle aches. This is normal. However, you should call for help immediately if you have increasing chest pain or shortness of breath, or if you cough up more than a few tablespoons of blood. Fever (temperature greater than 100.4&ordm;F or 38&ordm;C) is common after bronchoscopy, but usually for only for 24 hours. If fevers persist for longer than one day, you should contact your clinician.",
"    </p>",
"    <p>",
"     Preliminary results about the overall appearance of the airways are usually available immediately after bronchoscopy. Results of any biopsies or other tests take more time, depending upon the specific test that was done.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736498\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736506\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/43/22195?source=see_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/57/40850?source=see_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/23/24946?source=see_link\">",
"      Patient information: Multiple pulmonary nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/1/23570?source=see_link\">",
"      Patient information: Single pulmonary nodule (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11736523\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=see_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21511?source=see_link\">",
"      Fluorescence bronchoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37394?source=see_link\">",
"      Rigid bronchoscopy: Instrumentation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Thoracic Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thoracic.org\">",
"      www.thoracic.org",
"     </a>",
"     , click on Patient Education)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Chest Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.chestnet.org/patients/guides/\">",
"      www.chestnet.org/patients/guides/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart Lung &amp; Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/index.htm\">",
"      www.nhlbi.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?32/14/32993/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/14/32993?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/2\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/3\">",
"      Prakash UB, Offord KP, Stubbs SE. Bronchoscopy in North America: the ACCP survey. Chest 1991; 100:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/4\">",
"      Pue CA, Pacht ER. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995; 107:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/5\">",
"      Cordasco EM Jr, Mehta AC, Ahmad M. Bronchoscopically induced bleeding. A summary of nine years' Cleveland clinic experience and review of the literature. Chest 1991; 100:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/6\">",
"      Yigla M, Oren I, Bentur L, et al. Incidence of bacteraemia following fibreoptic bronchoscopy. Eur Respir J 1999; 14:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/7\">",
"      Poi PJ, Chuah SY, Srinivas P, Liam CK. Common fears of patients undergoing bronchoscopy. Eur Respir J 1998; 11:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/8\">",
"      Dubois JM, Bartter T, Pratter MR. Music improves patient comfort level during outpatient bronchoscopy. Chest 1995; 108:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32993/abstract/9\">",
"      Colt HG, Powers A, Shanks TG. Effect of music on state anxiety scores in patients undergoing fiberoptic bronchoscopy. Chest 1999; 116:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f32_14_32993=[""].join("\n");
var outline_f32_14_32993=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BRONCHOSCOPY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR BRONCHOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PREPARATIONS FOR FLEXIBLE BRONCHOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           FLEXIBLE BRONCHOSCOPY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           FLEXIBLE BRONCHOSCOPY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           CARE FOLLOWING FLEXIBLE BRONCHOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41237\" title=\"figure 1\">",
"           Normal lung anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/7/27762\" title=\"figure 2\">",
"           Flexible bronchoscope",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_32994="Sellar mass MRI III";
var content_f32_14_32994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sellar mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI shows enhancement of only the rim of a suprasellar mass (M) and of the normal pituitary inferior to it following the administration of gadolinium. The clear distinction between the mass and the normal pituitary indicates that the mass is not a pituitary adenoma. The mass was found on surgery to be a craniopharyngioma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Snyder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32994=[""].join("\n");
var outline_f32_14_32994=null;
var title_f32_14_32995="Nasal foreign body removal with a balloon catheter";
var content_f32_14_32995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nasal foreign body removal with a balloon catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The catheter (5 to 8 French Foley or Fogarty balloon catheter) is lubricated with 2 percent lidocaine jelly and advanced past the object. The balloon is then inflated with 2 to 3 mL of air, and the catheter is withdrawn from the nose with the object.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32995=[""].join("\n");
var outline_f32_14_32995=null;
var title_f32_14_32996="Rilpivirine: Patient drug information";
var content_f32_14_32996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rilpivirine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     see \"Rilpivirine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12891404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Edurant&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13265550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Edurant&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12990621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12990629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473507",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rilpivirine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours before this drug or 4 hours after this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12990627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12990625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12990623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16782 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32996=[""].join("\n");
var outline_f32_14_32996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12891404\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265550\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990621\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990629\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990618\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990626\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990627\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990622\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990625\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990620\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990623\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990624\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=related_link\">",
"      Rilpivirine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_32997="Periphlebitis";
var content_f32_14_32997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis, periphlebitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An area of central vein \"periphlebitis\". The venule wall, blue, is thicker than in the normal liver and is penetrated by mononuclear inflammatory cells. There is one swollen necrotic hepatocyte and replacement of dead hepatocytes by mononuclear inflammatory cells. \"Periphlebitis\" also occurs in rejection after liver transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32997=[""].join("\n");
var outline_f32_14_32997=null;
var title_f32_14_32998="Cyclebeads";
var content_f32_14_32998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    CycleBeads&reg; used with the standard days method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32998=[""].join("\n");
var outline_f32_14_32998=null;
var title_f32_14_32999="Renal toxicity of lithium";
var content_f32_14_32999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal toxicity of lithium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     Edgar V Lerma, MD, FACP, FASN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/32999/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/14/32999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ingestion in patients with bipolar (manic-depressive) illness has been associated with several different forms of renal injury. Nephrogenic diabetes insipidus (NDI) is the most common renal side effect of lithium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant form of chronic renal disease associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy is a chronic tubulointerstitial nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the majority of studies show infrequent and relatively mild renal insufficiency attributable to lithium therapy, end-stage renal disease (ESRD) secondary to lithium-associated chronic tubulointerstitial nephropathy does occur in a small percentage of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ]. Relatively less is known about potential glomerular toxicity of lithium, particularly the nephrotic syndrome. Additional kidney manifestations of lithium exposure include renal tubular acidosis and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=see_link\">",
"     \"Lithium poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEPHROGENIC DIABETES INSIPIDUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, water permeability of principal cells in the collecting tubule is regulated by antidiuretic hormone (ADH). Aquaporin-2 water channels (AQP2), which normally reside in the endosomes of principal cells, move to and fuse with the luminal membrane under the influence of ADH, thereby allowing water to be reabsorbed down the favorable concentration gradient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link&amp;anchor=H2#H2\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Actions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ingestion can lead to resistance to ADH, resulting in polyuria and polydipsia in up to 20 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Lithium enters the principal cells of the collecting duct through epithelial sodium channels in the luminal membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. It then accumulates in these cells and interferes with the ability of ADH to increase water permeability. Several possible mechanisms may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/1,8,10-13\">",
"     1,8,10-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    may increase expression of cyclooxegenase-2 and therefore increase urinary prostaglandin E2 excretion by medullary interstitial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/12\">",
"     12",
"    </a>",
"    ]. These prostaglandins then act on principal cells to induce lysosomal degradation of AQP2 water channels and a decline in urine concentrating ability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      may reduce AQP2 gene transcription, an effect that is prostaglandin independent, leading to a further decrease in concentrating ability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      induces collecting duct remodeling characterized by a decreased population of principal cells relative to the number of intercalated cells, a phenomenon that is most likely related to apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With chronic use in humans, nephrogenic diabetes insipidus often becomes irreversible. In one study, patients who had been on the drug for more than 18 years invariably had an irreversible defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute onset of nocturia is an important clue to the presence of nephrogenic diabetes insipidus. The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight; as a result, the first manifestation of a loss of concentrating ability is often nocturia.",
"   </p>",
"   <p>",
"    It should not be assumed that polyuria in a patient taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is due to nephrogenic diabetes insipidus. Both central diabetes insipidus (CDI) and primary polydipsia have also been described in patients treated with lithium; they may be induced by lithium or reflect underlying psychiatric disease, particularly the use of psychotropic medications, which induce a dry mouth, thereby stimulating thirst and producing a picture of primary polydipsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3,14,15\">",
"     3,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, a water restriction test should be performed to establish the correct diagnosis, since the treatment of these disorders is different. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of hyponatremia\", section on 'Primary polydipsia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although usually at least partially reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/16\">",
"     16",
"    </a>",
"    ], the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced concentrating defect may be permanent after prolonged therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. When lithium-induced nephrogenic diabetes insipidus is diagnosed, the following measures should be instituted. These modalities are most effective if the diagnosis is made before a severe concentrating defect has occurred:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      should be discontinued, if possible.",
"     </li>",
"     <li>",
"      For those patients in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      therapy is absolutely necessary despite its renal toxicity, we recommend the concomitant use of the potassium sparing diuretic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    inhibits the epithelial sodium channels in collecting tubule cells (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ) and therefore should minimize further accumulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (if lithium therapy is continued). The following data support the use of amiloride in patients with nephrogenic diabetes insipidus who continue to use lithium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       Amiloride",
"      </a>",
"      was given to nine patients who continued to take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      despite the development of nephrogenic diabetes insipidus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/9\">",
"       9",
"      </a>",
"      ]. After three to four weeks of therapy, mean urine volume fell significantly (from 4.7 to 3.1 liters per day), and urine osmolality increased significantly (from 228 to 331",
"      <span class=\"nowrap\">",
"       mosm/kg).",
"      </span>",
"      This effect persisted for at least six months.",
"     </li>",
"     <li>",
"      In a placebo-controlled crossover study, 11 patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      -induced nephrogenic diabetes insipidus were treated with 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      or placebo in random order for six weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/18\">",
"       18",
"      </a>",
"      ]. Amiloride therapy significantly increased the responsiveness of the urine osmolality to exogenous arginine vasopressin (165 percent increase in urine osmolality); no change in responsiveness to arginine vasopressin was seen with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    is likely to be effective only when there is a mild to moderate concentrating defect that is potentially reversible. The experience with amiloride has been disappointing in patients with severe disease (maximum urine osmolality below 200",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    In these patients, the tubular damage is often permanent, even if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]; as a result, diminishing lithium entry into the collecting tubular cells cannot improve concentrating ability.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    therapy is given, serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    concentrations must be carefully monitored, since diuretic induced volume depletion may increase proximal sodium and lithium reabsorption. The ensuing fall in lithium excretion may then require a reduction in drug dosage.",
"   </p>",
"   <p>",
"    Other therapeutic options to manage polyuria in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced nephrogenic diabetes insipidus are similar to those in other causes of nephrogenic diabetes insipidus: a thiazide diuretic (to diminish distal water delivery or upregulate aquaporin receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/19\">",
"     19",
"    </a>",
"    ]) and a nonsteroidal antiinflammatory drug (to decrease the synthesis of prostaglandins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another well-accepted regimen is the use of the combination of low-sodium diet and thiazide diuretics. Thiazides decrease urine volume and increase urine osmolality by producing a state of mild sodium depletion; this reduces distal tubule delivery of sodium and increases fractional water reabsorption in the collecting duct. As with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    concentrations",
"    <strong>",
"     must",
"    </strong>",
"    be closely monitored after initiation of therapy with a thiazide diuretic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since most patients have only partial resistance to ADH, it is also possible that attaining supraphysiologic levels of ADH (by administering dDAVP) will attenuate the polyuria. The likelihood of success may be increased by combining dDAVP with an NSAID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/20\">",
"     20",
"    </a>",
"    ]. NSAID therapy alone also may be effective in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of hypernatremia and its complications is also considerable in these patients. This is particularly true in settings in which fluid intake is curtailed, during an acute illness, or when inadequate fluid resuscitation is given in those undergoing surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RENAL TUBULAR ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tubular defect in the distal nephron can also impair the ability to maximally acidify the urine. This is most often manifested as the incomplete form of type 1 (distal) renal tubular acidosis, in which the urine pH is persistently above 5.3, but the extracellular pH and bicarbonate concentration are within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    has infrequently been associated with the nephrotic syndrome. Most cases are due to minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], but focal segmental glomerulosclerosis (FSGS) has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. The mechanism by which lithium leads to glomerular injury is not completely understood, but the course is highly suggestive of an etiologic role for lithium (ie, epithelial toxicity). Proteinuria generally begins within 1.5 to 10 months after the onset of therapy and, in minimal change disease, completely or partially resolves in most patients one to four weeks after lithium is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/22\">",
"     22",
"    </a>",
"    ]. In several patients, reinstitution of lithium led to recurrent nephrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Corticosteroids have occasionally been required to induce remission; it is possible that the minimal change disease in such cases was unrelated to lithium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship to FSGS is less clear. In three patients, for example, cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    did not lead to resolution of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/24\">",
"     24",
"    </a>",
"    ], suggesting either no relation to lithium or possible secondary FSGS due to tubular injury induced by chronic lithium therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Edema during the manic phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -treated patients become edematous in the absence of overt renal, hepatic, or cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. How this occurs is not well understood, but two factors may contribute: a marked increase in sodium intake that may be induced in part by mania, and perhaps a lithium-induced reduction in maximum sodium excretory capacity that is of no importance when sodium intake is relatively normal. Affected patients present with the unusual combination of edema plus high rates of urinary sodium excretion that can exceed 200",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Serum lithium concentrations may also fall below the therapeutic range at this time due to enhanced urinary lithium excretion. Volume expansion appropriately decreases the proximal reabsorption of sodium; lithium reabsorption also falls, since it is reabsorbed via the same transporters as sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHRONIC INTERSTITIAL NEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use is associated with chronic kidney disease that occasionally progresses to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5-7,28\">",
"     5-7,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major risk factors for nephrotoxicity appear to be the duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    exposure and the cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/6\">",
"     6",
"    </a>",
"    ]. Other risk factors include episodes of acute intoxication, increased age, other co-morbid illnesses (eg, hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia), and concomitant use of other anti-psychotic medications. The degree of renal insufficiency is generally relatively mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic interstitial nephritis usually presents as the insidious development of renal insufficiency, with normal to only a mild degree of proteinuria, often in the setting of NDI. The degree of interstitial fibrosis on renal biopsy may be directly related to the duration and cumulative dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional histologic lesions may be suggestive of chronic interstitial nephritis due to lithium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In experimental animals fed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , there is a predominance of tubular lesions, ie, dilatation of tubules in the distal segments and collecting ducts; glomerulosclerosis tends to be a late event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In humans, the presence of tubular cysts, which have been demonstrated to be of distal and collecting tubular origin, probably correspond to these tubular lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5,31\">",
"       5,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such microcysts have also been demonstrated on magnetic resonance imaging and ultrasonographic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that 15 to 20 percent of patients develop a slowly progressive decline in glomerular filtration rate, which usually does not fall below 40 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3,6,14\">",
"     3,6,14",
"    </a>",
"    ]. Progressive renal failure with a serum creatinine concentration above 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    due solely to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/29\">",
"     29",
"    </a>",
"    ] but can occur if lithium is continued after otherwise unexplained renal insufficiency has developed. In a review of 74 patients with lithium-induced renal insufficiency from France, the mean loss of creatinine clearance was 2.3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year and, by age 65, 12 reached end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/6\">",
"     6",
"    </a>",
"    ]. The average latent period between the onset of lithium therapy and end-stage renal disease was 20 years.",
"   </p>",
"   <p>",
"    The course of the renal disease after discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is unpredictable. There may be some recovery of renal function, particularly with correction of hypovolemia. Progressive renal failure can occur among patients with significant renal insufficiency as is shown in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 7 of 9 patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      nephrotoxicity and a serum creatinine concentration of &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      progressed to end-stage renal disease even after stopping lithium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5\">",
"       5",
"      </a>",
"      ]. Among ten patients who had an initial serum creatinine less than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      only one developed end-stage renal disease.",
"     </li>",
"     <li>",
"      Another study identified 18 patients with end-stage renal disease among 3369",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      treated patients in two regions of Sweden, a sixfold higher prevalence of disease than in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/7\">",
"       7",
"      </a>",
"      ]. Of these, thirteen had discontinued lithium for at least two years prior to starting dialysis. Eleven patients had serum creatinine concentrations greater than 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (125",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at the time that lithium was discontinued; two patients had initial serum creatinine concentrations less than 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      However, both patients had even lower creatinine concentrations (less than 0.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [65",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      when lithium was started suggesting that a decline in renal function had occurred with lithium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progressive renal insufficiency after cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    may be due to secondary factors, such as systemic and intraglomerular hypertension, possibly resulting in secondary glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPERPARATHYROIDISM AND HYPERCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another complication of long-term therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    carbonate is hyperparathyroidism, with associated hypercalcemia and hypocalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several mechanisms by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    may increase serum calcium levels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing the threshold for the calcium sensing mechanism within the parathyroid gland [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/34\">",
"       34",
"      </a>",
"      ]. Thus, PTH secretion continues despite the presence of hypercalcemia.",
"     </li>",
"     <li>",
"      Inducing PTH overproduction via inhibiting the action of glycogen synthase kinase 3b(GSK 3b).",
"     </li>",
"     <li>",
"      Inhibiting calcium transport (influx) across cell membranes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As hypercalcemia develops, it is further confounded by renal failure and its progression, which leads to decreased urinary calcium excretion (hypocalciuria). Other findings associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced",
"    <span class=\"nowrap\">",
"     hypercalcemia/hyperparathyroidism",
"    </span>",
"    include a normal serum phosphorus level and an elevated serum magnesium level.",
"   </p>",
"   <p>",
"    There is a higher proportion of patients (33 percent) who develop parathyroid hyperplasia in those with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced hyperparathyroidism, compared to the proportion of hyperparathyroidism affecting the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/33\">",
"     33",
"    </a>",
"    ]. This is probably the reason why acute withdrawal of lithium does not necessarily translate into any significant change in serum calcium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/35\">",
"     35",
"    </a>",
"    ]. Because simple discontinuation of lithium carbonate therapy does not always lead to normalization of serum-intact PTH and calcium levels, surgical parathyroidectomy has been a common option in those patients.",
"   </p>",
"   <p>",
"    Case reports have been published in which the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    HCl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/33\">",
"     33",
"    </a>",
"    ], a calcimimetic, decreased or normalized the serum calcium, with some reduction of serum intact PTH levels, similar to its effect in patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], thereby averting the need for surgical treatment. It is believed that cinacalcet HCl can neutralize the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    on the calcium-sensing receptor of the parathyroid gland. However, the mechanisms that underlie this effect remain undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSSIBLE INTERACTION WITH ACE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence suggest that there may be an adverse interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    and angiotensin converting enzyme (ACE) inhibitors, leading to renal insufficiency that may be associated with lithium accumulation toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Although it is unclear if this interaction is real, the serum creatinine concentration and lithium levels must be closely monitored if a patient on lithium is begun on an ACE inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL INVESTIGATIONS OF ALTERNATIVE TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeic acid phenethyl ester (CAPE), a known component of honeybee propolis, was protective against oxidative stress induced by reactive oxygen species (ROS), commonly observed in ischemia-reperfusion and toxic injuries. Used in experimental rat models, CAPE was shown to be protective against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -induced tubular damage and oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    N-Acetylcysteine (NAC) has been demonstrated to be renoprotective and effective in preventing hypoperfusion and radiocontrast-induced nephropathy. Using experimental Sprague-Dawley rats, those given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    had significantly lower percentages of tubular necrosis and tubular lumen obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/32999/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27106318\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ingestion in patients with bipolar (manic-depressive) illness has been associated with a variety of renal diseases, particularly nephrogenic diabetes insipidus (NDI) and, less frequently, chronic tubulointerstitial nephropathy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 20 to 40 percent of patients who chronically take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      develop polyuria and polydipsia. In such patients, a water restriction test should be performed to establish the presence of NDI, since patients with bipolar illness may also develop central diabetes insipidus and primary polydipsia. NDI appears to result from lithium accumulation in collecting tubule cells, which interferes with the ability of antidiuretic hormone to increase water permeability. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nephrogenic diabetes insipidus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who develop NDI,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      therapy should be discontinued, if possible. However, for those patients in whom lithium therapy is absolutely necessary despite its renal effects, concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      therapy to minimize lithium accumulation in collecting tubule cells is recommended. Amiloride is likely to be effective only when there is a mild to moderate concentrating defect that is potentially reversible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of the polyuria in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      -induced disease is similar to that in other causes of nephrogenic diabetes insipidus: a thiazide diuretic (to diminish distal water delivery or upregulate aquaporin receptors), a nonsteroidal antiinflammatory drug (to decrease the synthesis of prostaglandins) provided renal function is preserved, and a low sodium diet. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since most patients have only partial resistance to ADH, it is also possible that attaining supraphysiologic levels of ADH (by administering dDAVP) will attenuate the polyuria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      use is associated with the insidious onset of chronic kidney disease due to chronic interstitial nephritis in up to 15 to 20 percent of patients. Major risk factors for nephrotoxicity appear to be the duration of lithium exposure and the cumulative dose. The degree of renal insufficiency is generally relatively mild, but may occasionally progress to end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic interstitial nephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The course of the renal disease after discontinuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      is unpredictable. There may be some recovery of renal function, particularly with correction of hypovolemia. However, progression of chronic kidney disease can occur. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic interstitial nephritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      may lead to hyperparathyroidism, hypercalcemia and hypocalciuria. Discontinuation of lithium therapy does not always lead to normalization of parathyroid hormone and calcium levels, and thus surgical parathyroidectomy is a common option in such patients.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"       Cinacalcet",
"      </a>",
"      HCl, a calcimimetic, may also reduce parathyroid hormone levels and a return the serum calcium to normal, thereby averting the need for surgical treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hyperparathyroidism and hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less commonly,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      therapy can be associated with distal renal tubular acidosis, minimal change disease, focal segmental glomerulosclerosis, and edema during episodes of mania. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal tubular acidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Nephrotic syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Edema during the manic phase'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/1\">",
"      Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol 2010; 23 Suppl 16:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/2\">",
"      McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/3\">",
"      Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/4\">",
"      Aurell M, Hestbech J. Lithium-induced uraemia. Lancet 1979; 1:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/5\">",
"      Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/6\">",
"      Presne C, Fakhouri F, No&euml;l LH, et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003; 64:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/7\">",
"      Bendz H, Sch&ouml;n S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/8\">",
"      Gr&uuml;nfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/9\">",
"      Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/10\">",
"      Ecelbarger CA. Lithium treatment and remodeling of the collecting duct. Am J Physiol Renal Physiol 2006; 291:F37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/11\">",
"      Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 2006; 291:F39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/12\">",
"      Kortenoeven ML, Schweer H, Cox R, et al. Lithium reduces aquaporin-2 transcription independent of prostaglandins. Am J Physiol Cell Physiol 2012; 302:C131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/13\">",
"      Li Y, Shaw S, Kamsteeg EJ, et al. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 2006; 17:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/14\">",
"      Bendz H, Aurell M, Balldin J, et al. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/15\">",
"      Movig KL, Baumgarten R, Leufkens HG, et al. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003; 182:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/16\">",
"      Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005; 45:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/17\">",
"      Shaikh BS, Nicholas GG, Miller FJ. Persistent nephrogenic diabetes insipidus after lithium carbonate. Ann Intern Med 1977; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/18\">",
"      Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008; 3:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/19\">",
"      Kim GH, Lee JW, Oh YK, et al. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol 2004; 15:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/20\">",
"      Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med 1991; 324:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/21\">",
"      Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/22\">",
"      Wood IK, Parmelee DX, Foreman JW. Lithium-induced nephrotic syndrome. Am J Psychiatry 1989; 146:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/23\">",
"      Alexander F, Martin J. Nephrotic syndrome associated with lithium therapy. Clin Nephrol 1981; 15:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/24\">",
"      Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988; 84:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/25\">",
"      Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/26\">",
"      Demers R, Heninger G. Pretibial edema and sodium retention during lithium carbonate treatment. JAMA 1970; 214:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/27\">",
"      Rose BD. An unusual disorder of salt and water balance. Kidney Int Suppl 1997; 59:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/28\">",
"      Kripalani M, Shawcross J, Reilly J, Main J. Lithium and chronic kidney disease. BMJ 2009; 339:b2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/29\">",
"      Waller DG, Edwards JG, Papasthatis-Papayanni S. A longitudinal assessment of renal function during treatment with lithium. Q J Med 1988; 68:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/30\">",
"      Walker RG, Escott M, Birchall I, et al. Chronic progressive renal lesions induced by lithium. Kidney Int 1986; 29:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/31\">",
"      Hansen HE, Hestbech J, S&oslash;rensen JL, et al. Chronic interstitial nephropathy in patients on long-term lithium treatment. Q J Med 1979; 48:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/32\">",
"      Farres MT, Ronco P, Saadoun D, et al. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 2003; 229:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/33\">",
"      Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis 2006; 48:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/34\">",
"      Spiegel AM, Rudorfer MV, Marx SJ, Linnoila M. The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab 1984; 59:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/35\">",
"      Bendz H, Sj&ouml;din I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/36\">",
"      Gregoor PS, de Jong GM. Lithium hypercalcemia, hyperparathyroidism, and cinacalcet. Kidney Int 2007; 71:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/37\">",
"      Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008; 57:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/38\">",
"      Lehmann K, Ritz E. Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment. Am J Kidney Dis 1995; 25:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/39\">",
"      Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004; 52:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/40\">",
"      Oktem F, Ozguner F, Sulak O, et al. Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester. Mol Cell Biochem 2005; 277:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/32999/abstract/41\">",
"      Efrati S, Averbukh M, Berman S, et al. N-Acetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant 2005; 20:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2358 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-27.109.116.13-8463E5C1AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_32999=[""].join("\n");
var outline_f32_14_32999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27106318\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEPHROGENIC DIABETES INSIPIDUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RENAL TUBULAR ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Edema during the manic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHRONIC INTERSTITIAL NEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPERPARATHYROIDISM AND HYPERCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSSIBLE INTERACTION WITH ACE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXPERIMENTAL INVESTIGATIONS OF ALTERNATIVE TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27106318\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2358|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9225?source=related_link\">",
"      Lithium poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_33000="Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases";
var content_f32_14_33000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33000/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/14/33000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (AA) amyloidosis is a disorder characterized by the extracellular tissue deposition of fibrils that are composed of fragments of serum amyloid A (SAA) protein, an acute phase reactant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AA amyloidosis may complicate a number of chronic inflammatory conditions, including rheumatoid arthritis, juvenile chronic polyarthritis, ankylosing spondylitis, inflammatory bowel disease, familial periodic fever syndromes, chronic infections, and certain neoplasms.",
"   </p>",
"   <p>",
"    The major causes and approach to diagnosis of AA amyloidosis, as well as the rheumatic manifestations of other forms of amyloidosis, are presented here. The clinical manifestations and treatment of AA amyloidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES AND RELATION TO RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall autopsy incidence of AA amyloidosis in western nations ranges from 0.5 to 0.86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The following frequency of underlying disorders has been found in large series of patients with AA amyloidosis from two large centers in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA) &mdash; 48 to 56 percent",
"     </li>",
"     <li>",
"      Ankylosing spondylitis &mdash; 5 to 8 percent",
"     </li>",
"     <li>",
"      Psoriatic arthritis &mdash; 4 to 5 percent",
"     </li>",
"     <li>",
"      Familial Mediterranean fever &mdash; 2 to 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two subsequent studies of patients with AA amyloidosis in the United Kingdom, the larger of which included 374 subjects, found the following associated diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      JIA &mdash; 7 to 48 percent",
"     </li>",
"     <li>",
"      Adult RA &mdash; 23 to 51 percent",
"     </li>",
"     <li>",
"      Ankylosing spondylitis &mdash; 0 to 12 percent",
"     </li>",
"     <li>",
"      Heredofamilial (eg, familial Mediterranean fever) &mdash; 9 to 11 percent",
"     </li>",
"     <li>",
"      Chronic infection &mdash; 9 to 15 percent",
"     </li>",
"     <li>",
"      Psoriatic arthritis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Crohn's disease &mdash; 2 to 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other parts of the world, heredofamilial causes and infections are responsible for a larger proportion of cases of AA amyloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, in Turkey, familial Mediterranean fever is the cause of more than 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other conditions that may be associated with AA amyloid include neoplasms, particularly renal cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/9\">",
"     9",
"    </a>",
"    ], non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/10\">",
"     10",
"    </a>",
"    ], unicentric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/11\">",
"     11",
"    </a>",
"    ] or multicentric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/12\">",
"     12",
"    </a>",
"    ] Castleman&rsquo;s disease, cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/13\">",
"     13",
"    </a>",
"    ], abuse of injected drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/14\">",
"     14",
"    </a>",
"    ], and hidradenitis suppurativa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common organ system involved in AA amyloid is the kidney (about 80 percent). This is usually characterized by glomerular amyloid deposition, typically leading to the nephrotic syndrome (",
"    <a class=\"graphic graphic_picture graphicRef63840 graphicRef78183 graphicRef54148 graphicRef75254 \" href=\"mobipreview.htm?43/14/44266\">",
"     picture 1A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. However, variant forms occur in which the deposits are predominantly vascular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/16\">",
"     16",
"    </a>",
"    ] or tubular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/17\">",
"     17",
"    </a>",
"    ], with some evidence indicating that the AA protein in these forms is biochemically distinct (",
"    <a class=\"graphic graphic_picture graphicRef80029 graphicRef63533 \" href=\"mobipreview.htm?36/0/36873\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Patients with these variant forms of renal amyloid may present with progressive renal failure, a relatively bland urinary sediment, and little proteinuria or may show signs of primary tubular dysfunction such as nephrogenic diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Susceptibility to AA amyloidosis among the various rheumatic diseases is determined by genetic (eg, SAA polymorphisms, MEFV genotype, etc) and environmental (eg, triggers to sustained elevations of SAA, cleavage of SAA by specific enzymes) factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postmortem incidence of amyloid complicating adult RA has generally ranged from 10 to 25 percent, although older studies report 60 percent involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/20\">",
"     20",
"    </a>",
"    ]. Similar values of 11 to 29 percent have been found with subcutaneous fat pad aspirates or gastrointestinal biopsies in living patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. In these studies, AA amyloid was clinically overt in only 25 to 50 percent, even after long periods of follow-up sampling, indicating the majority of cases to be subclinical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lower frequency of symptomatic disease diagnosed pre-mortem that has ranged from 2 to 11 percent, with considerable variation between geographic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. In a population based series of 1666 subjects with RA who had died in Finland, the prevalence of amyloidosis was 5.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/27\">",
"     27",
"    </a>",
"    ]. The yield of amyloid among patients with RA and renal disease ranges from 10 to 30 percent.",
"   </p>",
"   <p>",
"    Amyloidosis is more likely to occur in patients with poorly controlled, seropositive, severe, and longstanding disease occurring in association with other extraarticular manifestations. The clinical spectrum of amyloidosis in RA was evaluated in a report of 124 patients from Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/23\">",
"     23",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-nine percent had signs of nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37812?source=see_link\">",
"       \"Renal disease in patients with rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fifty-eight percent had gastrointestinal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12280?source=see_link\">",
"       \"Gastrointestinal amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Forty percent had signs of cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mean duration of RA at diagnosis of amyloidosis was 15.4 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a retrospective review of 91 Dutch patients with AA amyloidosis due to RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/2\">",
"     2",
"    </a>",
"    ]. Nephropathy was the most common presenting symptom, being manifested as proteinuria (70 percent) or impaired renal function. Other organ systems were less frequently involved: cardiomyopathy (9 percent), gastrointestinal symptoms (24 percent), and hepatomegaly (19 percent).",
"   </p>",
"   <p>",
"    Unless the underlying RA can be effectively treated, the development of amyloidosis has traditionally been associated with a relatively poor prognosis. It has been estimated to be the cause of death of 2 to 8 percent of adult patients coming to autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/20\">",
"     20",
"    </a>",
"    ]. An earlier study from Japan found a four-year survival rate of 58 percent from the time of diagnosis of amyloidosis, with renal failure contributing to 39 percent of deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/23\">",
"     23",
"    </a>",
"    ]; a subsequent series a decade later reported an improvement in survival to a mean of 67 months following the diagnosis of AA amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/28\">",
"     28",
"    </a>",
"    ]. The study from Finland noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/27\">",
"     27",
"    </a>",
"    ] found that the diagnosis of amyloidosis shortened the lifespan of RA patients by 7.7 years; a reevaluation of autopsy material for the period from 1952 to 1991 from Finland reported a 30 percent incidence of AA amyloid compared with 18 percent detected on routine testing, indicating that a significant proportion of patients may not have been appreciated by standard histologic analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. By contrast to the time period sampled above, more recent (1987 to 1997) surveys from Finland appear to be confirming a decreasing incidence of AA amyloid among RA patients, possibly reflecting the impact of biological response modifiers and of more aggressive treatment standards for early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early reviews, juvenile chronic polyarthritis, also known as juvenile idiopathic arthritis (JIA), accounted for 43 percent of cases of amyloidosis occurring under age 18, with a 4 to 6 percent incidence reported among 389 cases of systemic onset (Still&rsquo;s) disease followed over a 10-year period. The prevalence of reactive amyloidosis in JIA varies from 1 to 10 percent, with considerable geographic variation (0.1 percent in the United States versus as high as 10.6 percent in Poland) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal involvement, manifested clinically as proteinuria, occurs in almost all affected patients. Symptomatic disease is also relatively common. One report, for example, found the following frequency of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Edema &mdash; 53 percent",
"     </li>",
"     <li>",
"      Hypertension &mdash; 25 percent",
"     </li>",
"     <li>",
"      End-stage renal disease &mdash; 2.5 percent",
"     </li>",
"     <li>",
"      Severe abdominal pain, hepatomegaly, and splenomegaly &mdash; about 20 percent each",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 13 percent",
"     </li>",
"     <li>",
"      Ascites &mdash; 2.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Amyloidosis was estimated to be the cause of death of 43 to 47 percent of European patients with this JIA in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/20\">",
"     20",
"    </a>",
"    ]. However, mortality due to AA amyloidosis may have decreased since the introduction of more effective treatments that lessen the chronic inflammation associated with systemic onset JIA, and there have been no further cases of JIA-associated AA amyloidosis documented in the Finnish registry since 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ankylosing spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less commonly observed than in RA, ankylosing spondylitis is a well-established cause of reactive amyloidosis, with renal involvement being the primary clinical manifestation. The Medical Research Council studies, performed in Britain in the 1950s, found a 6 percent incidence of amyloidosis in patients dying with AS; the diagnosis was made pre-mortem in only 11 of 25 affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/35\">",
"     35",
"    </a>",
"    ]. A 7 to 9 percent incidence has been reported in a series in which random rectal or fat pad biopsies were performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Subsequently, a 4.3 percent incidence was reported, primarily in patients with severe chronic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;AA amyloidosis has been described in only a small number of patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/39\">",
"     39",
"    </a>",
"    ]. The reason for the lower incidence of amyloidosis in SLE relative to RA is unknown but may be due to lower SAA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/40\">",
"     40",
"    </a>",
"    ] or, perhaps, to an increased predilection for circulating SAA to undergo proteolytic cleavage in RA compared with lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scattered case reports have noted reactive amyloidosis in a number of other rheumatic diseases. These include reactive arthritis (formerly Reiter syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/42\">",
"     42",
"    </a>",
"    ], psoriatic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/43\">",
"     43",
"    </a>",
"    ], Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/44\">",
"     44",
"    </a>",
"    ], Takayasu arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], Whipple&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/47\">",
"     47",
"    </a>",
"    ], polymyalgia rheumatica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/48\">",
"     48",
"    </a>",
"    ], giant cell arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/49\">",
"     49",
"    </a>",
"    ], gout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/50\">",
"     50",
"    </a>",
"    ], and Sj&ouml;gren&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hereditary AA amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AA amyloidosis can complicate heritable disorders characterized by periodic fevers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These disorders, which may also have rheumatic symptoms, are discussed separately and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial Mediterranean fever (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Familial cold autoinflammatory syndrome and Muckle-Wells syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor necrosis factor receptor-1 (TNFR1)-associated periodic syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28551?source=see_link\">",
"       \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyper-IgD syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=see_link\">",
"       \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Idiopathic AA amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of patients (7 percent in one large series), the underlying cause remains obscure, despite an extensive work-up for underlying inflammatory or infectious causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/6\">",
"     6",
"    </a>",
"    ]. In three well-characterized series of patients with AA amyloidosis from the United States, approximately 20 percent of cases were found to be idiopathic at diagnosis, with a small percentage revealing a known association later in the course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (AA) amyloidosis can affect a variety of organs, including the heart and kidneys. These manifestations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of AA amyloidosis may be suggested by clinical features and by the presence of a predisposing rheumatic or a chronic inflammatory disease (eg, nephrotic syndrome occurring in the setting of long standing RA), tissue biopsy is necessary to confirm the presence of amyloid, and additional laboratory testing may be needed to exclude other conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H20#H20\">",
"     \"An overview of amyloidosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We take the following approach to diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend tissue biopsy in all cases of suspected AA amyloidosis to confirm the presence of amyloid. The abdominal fat is a generally safe and reasonably sensitive site for initial biopsy. If a fat aspiration biopsy is negative, then a rectal biopsy or biopsy of a clinically involved organ is recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H21#H21\">",
"       \"An overview of amyloidosis\", section on 'Biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If amyloid is present, further immunofluorescence or immunochemical staining for serum amyloid A protein and for kappa and lambda light chains is indicated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Biopsy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We recommend testing of serum and urine for monoclonal immunoglobulins and of serum for free light chains to exclude AL amyloidosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory testing'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of the subcutaneous fat, rectal tissue, bone marrow, or a clinically involved organ may be used to document the presence of amyloid. These techniques are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H21#H21\">",
"     \"An overview of amyloidosis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, immunofluorescence (as well as immunohistochemical and immunoelectron) microscopy with a monospecific anti-AA protein antiserum is typically markedly positive in AA amyloidosis (",
"    <a class=\"graphic graphic_picture graphicRef75254 \" href=\"mobipreview.htm?35/29/36306\">",
"     picture 1D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Absence of staining for lambda or kappa light chains further helps to distinguish AA from AL amyloidosis. Amino acid sequencing and mass spectroscopy of amyloid deposits have been utilized to identify the precursor protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/57-59\">",
"     57-59",
"    </a>",
"    ] and are available commercially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/60\">",
"     60",
"    </a>",
"    ]. Quantitation of AA amyloid in abdominal fat pad aspirates has been demonstrated using an enzyme-linked immunosorbent assay (ELISA); this approach may have utility for comparing patient population, and for monitoring AA deposition serially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33000/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the biopsy-related studies described above, laboratory testing has little role in confirming the presence of AA amyloidosis. However, tests for monoclonal immunoglobulins in serum, such as immunofixation and measurement of free immunoglobulin light chains, are essential in excluding AL amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     SAP scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid fibrils avidly bind both apolipoprotein E and a normal circulating protein of uncertain physiologic significance called serum amyloid P component (SAP). Tissue amyloid deposits may be identifiable by scintigraphy following the intravenous injection of technetium or radioiodine-labeled SAP. The sensitivity and specificity of SAP scanning are discussed in detail elsewhere. This test is not available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link&amp;anchor=H1666860#H1666860\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Serum amyloid P component scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of biopsy established amyloidosis, the differential diagnosis of AA amyloidosis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary (AL) amyloidosis",
"      </strong>",
"      &mdash; AL amyloidosis is due to the tissue deposition of fragments of monoclonal immunoglobulin light chains. The plasma cell proliferation in this disorder leads to the presence of a paraprotein in the serum (as an M protein on protein immunoelectrophoresis, on immunofixation, or evidenced by increased serum free light chains) or urine (as monoclonal light chains) in approximately 90 percent of cases. Although virtually all patients have multisystem amyloid deposition, it is not uncommon to present with organ-dominant disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"       \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who have a monoclonal gammopathy of undetermined significance (MGUS) may require additional diagnostic studies as approximately 10 percent of such patients have been found to have a type of amyloidosis other than AL amyloid.",
"     </li>",
"     <li>",
"      <strong>",
"       Hereditary amyloidosis",
"      </strong>",
"      &mdash; Heritable amyloidoses result from mutations in gene coding for one of several different proteins. A thorough family history aids in the exclusion of these heritable disorders. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hereditary AA amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dialysis-related amyloidosis",
"      </strong>",
"      &mdash; Dialysis-related amyloidosis is due to deposition of fibrils derived from beta-2 microglobulin, which accumulates in patients with end-stage renal disease who are being maintained for prolonged periods of time by dialysis. This disorder has a predilection for osteoarticular structures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=see_link\">",
"       \"Dialysis-related amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Age-related (senile) systemic amyloidosis",
"      </strong>",
"      &mdash; Deposition of otherwise normal (wild-type) transthyretin in myocardium and other sites is referred to as systemic senile amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H8#H8\">",
"       \"An overview of amyloidosis\", section on 'Age-related (senile) systemic amyloidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Organ-specific amyloidosis",
"      </strong>",
"      &mdash; The coincidental occurrence of organ-specific amyloidosis in a patient with a systemic rheumatic or a chronic inflammatory disorder could cause confusion with AA amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H9#H9\">",
"       \"An overview of amyloidosis\", section on 'Organ-specific amyloid'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary (AA) amyloidosis is a disorder characterized by the extracellular tissue deposition of fibrils that are composed of fragments of serum amyloid A (SAA) protein, an acute phase reactant. AA amyloidosis may complicate a number of chronic inflammatory conditions. The overall autopsy incidence of AA amyloidosis in western nations ranges from 0.5 to 0.86 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes and relation to rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common underlying disorders associated with AA amyloidosis in the United States and in northern Europe include (in approximate descending order of frequency) are rheumatoid arthritis, juvenile chronic polyarthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis, familial periodic fever syndromes, chronic infections, and certain neoplasms.",
"      <br/>",
"      <br/>",
"      In other parts of the world, heredofamilial causes and infections are responsible for a larger proportion of cases of AA amyloid. Susceptibility to AA amyloidosis among the various rheumatic diseases is determined by genetic and environmental factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes and relation to rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend tissue biopsy in all cases of suspected AA amyloidosis to confirm the presence of amyloid. The abdominal fat is a generally safe and reasonably sensitive site for initial biopsy. If a fat aspiration biopsy is negative, then a rectal biopsy or biopsy of a clinically involved organ is recommended. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link&amp;anchor=H21#H21\">",
"       \"An overview of amyloidosis\", section on 'Biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If amyloid is present, further immunofluorescence or immunochemical staining for serum amyloid A protein and for kappa and lambda light chains is indicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend testing of serum and urine for monoclonal immunoglobulins and of serum for free light chains to exclude AL amyloidosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of biopsy-established amyloidosis, the differential diagnosis of AA amyloidosis includes primary (AL) amyloidosis, hereditary amyloidosis, dialysis-related amyloidosis, age-related systemic amyloidosis, and organ-specific amyloidosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/1\">",
"      Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994; 8:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/2\">",
"      Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis 2000; 59:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/3\">",
"      Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991; 70:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/4\">",
"      Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/5\">",
"      Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM 2000; 93:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/6\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/7\">",
"      Westermark P, Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 2008; 363:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/8\">",
"      Ensari C, Ensari A, T&uuml;mer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant 2005; 20:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/9\">",
"      Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med 1982; 73:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/10\">",
"      Piskin O, Alacacioglu I, Ozkal S, et al. A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. J BUON 2008; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/11\">",
"      Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease. Amyloid 2006; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/12\">",
"      Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007; 68:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/13\">",
"      Skinner M, Pinnette A, Travis WD, et al. Isolation and sequence analysis of amyloid protein AA from a patient with cystic fibrosis. J Lab Clin Med 1988; 112:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/14\">",
"      Manner I, Sagedal S, R&oslash;ger M, Os I. Renal amyloidosis in intravenous heroin addicts with nephrotic syndrome and renal failure. Clin Nephrol 2009; 72:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/15\">",
"      Girouard SD, Falk RH, Rennke HG, Merola JF. Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J 2012; 18:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/16\">",
"      Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989; 30:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/17\">",
"      Hiki Y, Horii A, Kokubo T, et al. A case of rheumatoid arthritis with renal tubular amyloidosis. Nephron 1994; 68:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/18\">",
"      Westermark GT, Sletten K, Grubb A, Westermark P. AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am J Pathol 1990; 137:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/19\">",
"      Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/20\">",
"      Husby G. Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatol 1985; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/21\">",
"      P&auml;i S, Helin H, Isom&auml;ki H. Frequency of amyloidosis in Estonian patients with rheumatoid arthritis. Scand J Rheumatol 1993; 22:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/22\">",
"      G&oacute;mez-Casanovas E, Sanmart&iacute; R, Sol&eacute; M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/23\">",
"      Okuda Y, Takasugi K, Oyama T, et al. [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases]. Ryumachi 1994; 34:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/24\">",
"      Wakhlu A, Krisnani N, Hissaria P, et al. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003; 30:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/25\">",
"      El Mansoury TM, Hazenberg BP, El Badawy SA, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002; 61:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/26\">",
"      Wiland P, Wojtala R, Goodacre J, Szechinski J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol 2004; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/27\">",
"      Myllykangas-Luosuj&auml;rvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) 1999; 38:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/28\">",
"      Kuroda T, Tanabe N, Harada T, et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2006; 25:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/29\">",
"      Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/30\">",
"      Koivuniemi R, Paimela L, Suomalainen R, et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/31\">",
"      Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999; 18:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/32\">",
"      David J, Vouyiouka O, Ansell BM, et al. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/33\">",
"      Woo P. Amyloidosis in children. Baillieres Clin Rheumatol 1994; 8:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/34\">",
"      Immonen K, Savolainen A, Kautiainen H, Hakala M. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J Rheumatol 2008; 35:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/35\">",
"      CRUICKSHANK B. Pathology of ankylosing spondylitis. Bull Rheum Dis 1960; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/36\">",
"      Gratacos J, Orellana C, Sanmarti R, et al. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997; 24:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/37\">",
"      Kovacsovics-Bankowski M, Zufferey P, So AK, Gerster JC. Secondary amyloidosis: a severe complication of ankylosing spondylitis. Two case-reports. Joint Bone Spine 2000; 67:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/38\">",
"      Singh G, Kumari N, Aggarwal A, et al. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007; 34:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/39\">",
"      Aktas Yilmaz B, D&uuml;zg&uuml;n N, Mete T, et al. AA amyloidosis associated with systemic lupus erythematosus: impact on clinical course and outcome. Rheumatol Int 2008; 28:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/40\">",
"      Pepys MB. Serum C-reactive protein, serum amyloid P-component and serum amyloid A protein in autoimmune disease. Clin Immunol Allergy 1981; 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/41\">",
"      Migita K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/42\">",
"      Anderson CJ, Gregory MC, Groggel GC, Clegg DO. Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis 1989; 14:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/43\">",
"      Mpofu S, Teh LS, Smith PJ, et al. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) 2003; 42:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/44\">",
"      Akpolat T, Dilek M, Aksu K, et al. Renal Beh&ccedil;et's disease: an update. Semin Arthritis Rheum 2008; 38:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/45\">",
"      Wada Y, Nishida H, Kohno K, et al. AA amyloidosis in Takayasu's arteritis--long-term survival on maintenance haemodialysis. Nephrol Dial Transplant 1999; 14:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/46\">",
"      Nakamura S, Morishita M, Yang CL, et al. An elderly female who survived more than 30 years following a diagnosis of Takayasu's arteritis, complicated by fatal intestinal amyloidosis. Clin Rheumatol 2006; 25:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/47\">",
"      Cruz I, Oliveira AP, Lopes JM, et al. Whipple's disease and renal amyloidosis. Am J Gastroenterol 1993; 88:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/48\">",
"      Escrib&aacute; A, Morales E, Albiz&uacute;a E, et al. Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica. Am J Kidney Dis 2000; 35:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/49\">",
"      Sicilia JJ, Blanco J, Ubeda I. Giant cell arteritis and renal amyloidosis: report of a case. Clin Nephrol 2001; 56:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/50\">",
"      Gum&aacute; M, Bay&eacute;s B, Bonet J, Oliv&eacute; A. Gout and secondary amyloid. Clin Rheumatol 1999; 18:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/51\">",
"      Wong BC, Wong KL, Ip MS, et al. Sj&ouml;gren's syndrome with amyloid A presenting as multiple pulmonary nodules. J Rheumatol 1994; 21:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/52\">",
"      Girnius S, Dember L, Doros G, Skinner M. The changing face of AA amyloidosis: a single center experience. Amyloid 2011; 18 Suppl 1:226.",
"     </a>",
"    </li>",
"    <li>",
"     Kluve-Beckerman B, Benson MD. AA amyloidosis in patients with no known inflammatory condition. Abstract PB15. XIII Intl Symposium on Amyloidosis, May 6-10, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/54\">",
"      Bunker D, Gorevic PD. AA amyloidosis: The Mount Sinai Experience, 1997-2012. Mt Sinai J Med.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/55\">",
"      Yang GC, Gallo GR. Protein A-gold immunoelectron microscopic study of amyloid fibrils, granular deposits, and fibrillar luminal aggregates in renal amyloidosis. Am J Pathol 1990; 137:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/56\">",
"      Picken MM, Pelton K, Frangione B, Gallo G. Primary amyloidosis A. Immunohistochemical and biochemical characterization. Am J Pathol 1987; 129:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/57\">",
"      Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol 2006; 412:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/58\">",
"      Hazenberg BP, Bijzet J, Limburg PC, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33000/abstract/59\">",
"      Lavatelli F, Perlman DH, Spencer B, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7:1570.",
"     </a>",
"    </li>",
"    <li>",
"     Dogan A. Classification of amyloidosis by mass spectometry-based proteomics. In: Amyloid &amp; Related Disorders: Surgical Pathology &amp; Clinical Correlations, Pickens MM, et al.  (Eds), Springer, 2012. p.261.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5602 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33000=[""].join("\n");
var outline_f32_14_33000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES AND RELATION TO RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ankylosing spondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hereditary AA amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Idiopathic AA amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SAP scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5602|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/25/33177\" title=\"picture 1A\">",
"      Amyloid light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/17/38162\" title=\"picture 1B\">",
"      Congo red amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/58/22441\" title=\"picture 1C\">",
"      Amyloid EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/29/36306\" title=\"picture 1D\">",
"      Amyloid AA IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/63/41971\" title=\"picture 2A\">",
"      Vascular amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/27/31158\" title=\"picture 2B\">",
"      Tubular amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37812?source=related_link\">",
"      Renal disease in patients with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_33001="Genital herpes simplex virus infection and pregnancy";
var content_f32_14_33001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genital herpes simplex virus infection and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Laura E Riley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/14/33001/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/14/33001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) infection is prevalent worldwide among women of childbearing age. During pregnancy, the major concern of maternal HSV infection is transmission to the fetus, as neonatal infection can result in serious morbidity and mortality. The major issues related to genital herpes infection in pregnancy will be reviewed here. The epidemiology, clinical manifestations, diagnosis, treatment, and prevention of primary and recurrent genital HSV infection in the general population, and issues related to management of the infected neonate, are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"       \"Treatment of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link\">",
"       \"Prevention of genital herpes virus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND SIGNIFICANCE OF HSV INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical designations of genital herpes simplex virus (HSV) infection include: primary, first episode genital nonprimary, and recurrent infection (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both serologic and virologic assays are usually required for accurate designation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/1\">",
"     1",
"    </a>",
"    ], except in the case of well-documented recurrent genital herpes previously confirmed by culture or polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/1\">",
"     1",
"    </a>",
"    ]. Accurate classification of infection is particularly important during pregnancy, since newly acquired (primary or first episode genital nonprimary) infection near delivery is a major risk factor for transmission to the neonate. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Predictors of neonatal infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary genital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary genital infection refers to the first occurrence of HSV infection. These patients do not have preexisting antibodies to either HSV-1 or HSV-2. Type-specific antibodies to HSV generally develop within the first 12 weeks after infection and persist indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of primary HSV infection during pregnancy was evaluated in a prospective study of over 7000 pregnant women who were seronegative for HSV-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HSV-2 at the first prenatal visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"     3",
"    </a>",
"    ]. Serum samples for antibodies directed at HSV-1 and HSV-2 were obtained at approximately 16 and 24 weeks of gestation and during labor. Seroconversion occurred in 94 women (1.3 percent) with similar frequency in all trimesters; 34 patients were symptomatic and 60 were asymptomatic around the time of HSV acquisition.",
"   </p>",
"   <p>",
"    The major consequence of primary infection is maternal-fetal transmission at the time of delivery. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Predictors of neonatal infection'",
"    </a>",
"    below.) The risks of other pregnancy complications, such as miscarriage, congenital anomalies, preterm birth, and intrauterine growth restriction, are probably not increased or only minimally increased because in",
"    <span class=\"nowrap\">",
"     utero/placental",
"    </span>",
"    HSV infection is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, in utero disease from transplacental or ascending infection has been reported anecdotally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=see_link&amp;anchor=H5#H5\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Intrauterine HSV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     First episode genital nonprimary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;First episode genital nonprimary infection refers to the first occurrence of genital HSV infection in a patient with preexisting HSV antibodies that are different from the HSV type recovered from the genitalia (ie, acquisition of genital HSV-2 infection in a patient with preexisting antibodies to HSV-1 or acquisition of genital HSV-1 lesions in a patient with preexisting antibodies to HSV-2). The major risk of primary infection is maternal-fetal transmission at the time of delivery. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Predictors of neonatal infection'",
"    </a>",
"    below.) In utero infection is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recurrent genital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent genital infection refers to the occurrence of genital HSV infection in a patient seropositive for the HSV type recovered from the lesion. The risk of neonatal transmission at delivery is much lower than in patients with primary or first episode genital infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Recurrent HSV has not been associated with miscarriage or embryopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14705932\">",
"    <span class=\"h1\">",
"     SEROPREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, herpes simplex virus type 2 (HSV-2) caused the majority of cases of virologically confirmed genital herpes infections. However, HSV-1 has increased in frequency and is estimated to be responsible for most new genital HSV infections in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seroprevalence rates of HSV-1 and HSV-2 in the United States were studied in pregnant females who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall, HSV-1 seroprevalence was 63 percent; HSV-2 seroprevalence was 22 percent. Of note, non-Hispanic white women were significantly more likely to be seronegative than other racial and ethnic groups (40 percent versus 11 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of genital herpes simplex virus (HSV) can vary widely depending upon whether the infection is primary or recurrent. Clinical findings are similar in pregnant and nonpregnant women, and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Primary infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Nonprimary infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Recurrent infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, the initial presentation of primary infection can be severe, with painful genital ulcers, pruritus, dysuria, fever, tender inguinal lymphadenopathy, and headache. In other cases, symptoms are mild or the patient is asymptomatic. The signs and symptoms of first episode genital nonprimary infection tend to be milder than in primary infection. In a study of pregnant women who developed primary HSV infection, only one-third had symptoms consistent with genital HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"     3",
"    </a>",
"    ]. Given the high frequency of asymptomatic or minimally symptomatic infection, the ability to identify pregnant women with genital herpes by patient history alone is limited.",
"   </p>",
"   <p>",
"    Patients with recurrent disease tend to have mild symptoms and few lesions, or no symptoms at all. In patients who develop lesions, prodromal symptoms, such as pruritus, burning, or pain, may occur before the lesions are visible. The genital lesions may be nontender or atypical in appearance (eg, fissure, vulvar irritation). The duration of lesions and viral shedding during recurrent infection are shorter than that seen during the primary episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14706735\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) infection can be diagnosed by viral culture, polymerase chain reaction (PCR), direct fluorescent antibody testing, and type-specific serologic tests. The choice of test depends on the clinical presentation. Diagnostic testing is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If active genital lesions are present, the vesicle may be unroofed for sampling of vesicular fluid for viral culture. However, the overall sensitivity of viral culture of genital lesions is only approximately 80 percent during primary HSV infection and 35 percent during recurrent infection.",
"     </li>",
"     <li>",
"      PCR is more sensitive than culture and is becoming the preferred test for diagnostic testing in symptomatic patients and for detecting viral shedding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/12-15\">",
"       12-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type-specific HSV serology is helpful for classifying maternal infection as primary, nonprimary, or recurrent (",
"      <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VERTICAL TRANSMISSION OF HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of herpes simplex virus (HSV) to neonates usually occurs during labor and delivery as a result of direct contact with virus shed from infected sites (vulva, vagina, cervix, perianal area). Importantly, viral shedding can occur when maternal symptoms and lesions are absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. Important principles for understanding the role of viral shedding in transmission of HSV infection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral shedding is more frequent during the first three months following resolution of primary HSV lesions than at later time points.",
"     </li>",
"     <li>",
"      The concentration and duration of viral shedding are higher with primary versus nonprimary disease and in HSV-2 versus HSV-1 infection.",
"     </li>",
"     <li>",
"      The rate of subclinical shedding of HSV in women with no reported history of genital herpes is similar to that in the subjects with such a history (3.0 percent versus 2.7 percent). These concepts are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, in utero infection occurs as a result of transplacental or ascending transmembranous infection, as suggested by the presence of early neonatal HSV infection despite delivery by cesarean before both labor and rupture of fetal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7,19\">",
"     7,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Predictors of neonatal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of neonatal infection is highest in women with a primary or first episode genital HSV infection acquired near the time of delivery. The risk of neonatal infection is somewhat lower in women with first episode genital nonprimary infection, and lowest in women with recurrent HSV. In two case series of women cultured on admission to labor and delivery and subsequently found to have positive results, the frequency of neonatal infection was: primary infection",
"    <span class=\"nowrap\">",
"     (2/5",
"    </span>",
"    [40 percent],",
"    <span class=\"nowrap\">",
"     4/9",
"    </span>",
"    [44 percent]), first episode genital nonprimary infection",
"    <span class=\"nowrap\">",
"     (4/13",
"    </span>",
"    [31 percent],",
"    <span class=\"nowrap\">",
"     4/17",
"    </span>",
"    [24 percent]), and recurrent infection",
"    <span class=\"nowrap\">",
"     (1/34",
"    </span>",
"    [3 percent],",
"    <span class=\"nowrap\">",
"     2/151",
"    </span>",
"    [1.3 percent]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that infants born to mothers with a first genital infection near the time of labor are at the highest risk of infection is likely related to both the absence of maternal type-specific anti-HSV antibodies and to greater viral exposure during primary infection. As discussed above, type-specific antibodies to HSV generally develop within the first 12 weeks after infection and persist indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ]. The significantly lower frequency of neonatal infection in recurrent infection is probably related to a protective role of HSV-specific maternal antibodies and lower concentration and duration of genital tract viral shedding during reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/20\">",
"     20",
"    </a>",
"    ]. Women with a primary infection or first episode genital nonprimary infection early in pregnancy who develop type-specific HSV antibodies before the onset of labor appear to be at a similar low risk of neonatal transmission as women with recurrent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the type of genital HSV (HSV-1 versus HSV-2) affects the risk of neonatal transmission and neonatal sequelae, clinical management of the pregnancy does not take HSV type into account and maternal serology to determine HSV type is not usually performed. &nbsp;",
"   </p>",
"   <p>",
"    In the presence of viral shedding, use of invasive fetal monitoring and preterm birth increase the risk of neonatal infection.",
"   </p>",
"   <p>",
"    These concepts are illustrated, in part, by the following seminal studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study between 1982 and 1999, 58,000 pregnant women in Washington state were classified as having primary, non-primary, or reactivation disease by comprehensive testing with serologic, culture, and polymerase chain reaction (PCR) techniques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7\">",
"       7",
"      </a>",
"      ]. HSV was isolated from the cervix and external genitalia in 202 (0.5 percent) women at the time of labor. The following observations were made in relation to neonatal infection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Viral genital shedding in labor was a strong predictor of neonatal HSV infection (OR 346). Neonatal HSV infection occurred in 5 percent",
"      <span class=\"nowrap\">",
"       (10/202)",
"      </span>",
"      of women with a positive HSV culture versus 0.02 percent",
"      <span class=\"nowrap\">",
"       (6/39,821)",
"      </span>",
"      of women with a negative culture.",
"     </li>",
"     <li>",
"      The highest risk of neonatal HSV infection was in neonates of women with newly acquired primary genital HSV who were HSV-seronegative: 54 per 100,000 live births compared with 26 per 100,000 live births when the mother was HSV-1-seropositive and 22 per 100,000 live births when the mother was HSV-2-seropositive.",
"     </li>",
"     <li>",
"      Other significant risk factors for neonatal HSV included HSV isolation from the cervix (OR 33), shedding HSV-1 rather than HSV-2 (OR 17), invasive fetal monitoring (OR 7), delivery before 38 weeks (OR 4), and maternal age &lt;21 years (OR 4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 7046 HSV-seronegative pregnant women followed throughout pregnancy, 94 developed primary infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"       3",
"      </a>",
"      ]. The time of acquisition of HSV infection was known for 60 of these pregnancies: 30 percent occurred in the first trimester, 30 percent in the second trimester, and 40 percent in the third trimester. Neonatal HSV infection occurred in 44 percent",
"      <span class=\"nowrap\">",
"       (4/9)",
"      </span>",
"      of infants born to women who acquired genital HSV infection shortly before labor (one of these infants died). Seven of the nine women with genital HSV infection shortly before labor had antibody to HSV-1 and were culture-positive for HSV-2 during labor, thus, they had non-primary genital infection; two of these seven women delivered infected neonates. The other two women were HSV-seronegative, but were HSV-1 culture-positive at delivery and transmitted HSV-1 to their neonates (",
"      <a class=\"graphic graphic_table graphicRef68522 \" href=\"mobipreview.htm?25/59/26556\">",
"       table 2",
"      </a>",
"      ). Seroconversion completed before labor was not associated with perinatal morbidity or any cases of neonatal HSV infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14708541\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decision-making regarding management of pregnant women with herpes simplex virus (HSV) must consider the category of infection (ie, primary genital, first genital episode nonprimary, or recurrent) and the timing of infection relative to delivery. Therapy should always be offered to patients with primary or first episode genital nonprimary infection, regardless of timing of occurrence during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment decreases the risks of severe or prolonged symptoms and a complicated infection in the mother. Treatment may be indicated for recurrent infection for symptomatic relief. Suppressive antiviral therapy is suggested at 36 weeks of gestation through delivery for women with a history of recurrent genital herpes to reduce the risk of lesions at the time of delivery.",
"   </p>",
"   <p>",
"    The treatment of primary and recurrent HSV infections in nonpregnant patients is discussed in detail separately; the following discussion will review only those issues related to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Safety of antiviral drugs in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both animal and human data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    exposure during pregnancy, including the first trimester, suggest that this drug is safe at all stages of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/22\">",
"     22",
"    </a>",
"    ]. Data are more limited but reassuring regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    . There are minimal human data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    exposure in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14708688\">",
"    <span class=\"h2\">",
"     Treatment of an acute episode",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Primary or first genital infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although newly acquired genital HSV is self-limited, we recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy (400 mg orally three times daily for 7 to 10 days; treatment can be extended if healing is incomplete after 10 days) to reduce the duration of active lesions and viral shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23\">",
"     23",
"    </a>",
"    ]. Antiviral therapy can also decrease the risk of complicated primary infection in the mother. For symptom control, analgesia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    can be considered along with sitz baths. Intravenous acyclovir is indicated for severe infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Complicated HSV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among nonpregnant patients, antiviral therapy of recurrent episodes is most likely to be effective if started within the first 24 hours of symptoms; however, most recurrences are short-lived and do not require intervention. Thus, many pregnant women and their physicians choose not to treat recurrences with antivirals during the first 35 weeks of pregnancy in order to limit unnecessary exposure to antiviral medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of suppressive therapy from 36 weeks of gestation to delivery reduces the frequency of symptomatic HSV recurrence at the onset of labor, and thus reduces the need for cesarean delivery (see",
"    <a class=\"local\" href=\"#H14710006\">",
"     'Evidence for cesarean delivery'",
"    </a>",
"    below). An important question in pregnant women is whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    suppresses viral shedding as well as symptomatic recurrence, since viral shedding may lead to neonatal exposure.",
"   </p>",
"   <p>",
"    This issue has been addressed by a meta-analysis of 7 randomized trials involving 1249 women with recurrent or first episode HSV infection during pregnancy who began",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or placebo prophylaxis at 36 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/24\">",
"     24",
"    </a>",
"    ]. Acyclovir significantly reduced the risk of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical HSV recurrence at the time of delivery (RR 0.28, 95% CI 0.18-0.43)",
"     </li>",
"     <li>",
"      Asymptomatic viral shedding at delivery (OR 0.14, 95% CI 0.05-0.39)",
"     </li>",
"     <li>",
"      Cesarean delivery for clinically recurrent genital herpes (RR 0.30, 95% CI 0.20-0.45)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, the American College of Obstetricians and Gynecologists (ACOG) recommends that suppressive antiviral therapy be offered at 36 weeks of gestation through delivery for women with a history of genital HSV to reduce the risk of recurrence at term, and thus the risk of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23\">",
"     23",
"    </a>",
"    ]. Women with one or more symptomatic genital HSV infections during pregnancy are most likely to benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although suppressive therapy markedly reduces the frequency of symptomatic disease and asymptomatic viral shedding, the effect on the incidence of neonatal herpes is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ]. Suppressive therapy does not completely eliminate viral shedding. A multicenter series of eight cases of neonatal herpes noted that all of the mothers were prescribed",
"    <span class=\"nowrap\">",
"     treatment/suppressive",
"    </span>",
"    therapy during pregnancy and five mothers were on suppressive therapy on the day of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/26\">",
"     26",
"    </a>",
"    ]. Among the five women on therapy at delivery, two infants were delivered by cesarean after 0 and 27 hours rupture of membranes, respectively, and three infants delivered vaginally after membrane rupture for 45 minutes, 12 hours, and 19 days, respectively. No woman had visible genital lesions at delivery. Of note, some of the mothers did not take all of their medication as prescribed. &nbsp;",
"   </p>",
"   <p>",
"    There are no studies examining the utility of suppressive therapy among HSV-2 seropositive women who do not have a history of genital herpes and were only diagnosed with HSV infection on the basis of serologic testing; we do not recommend antiviral therapy for them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14708874\">",
"    <span class=\"h3\">",
"     Drug and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the available antiviral medications (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ), the greatest clinical experience has been with acyclovir, dosed at 400 mg orally three times daily from 36 weeks of gestation until delivery. The rationale for three times daily dosing is the substantial elevation in glomerular filtration rates seen in pregnant women, which can lead to more rapid drug elimination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is an alternative, although it is usually a more expensive option (including generic valacyclovir) with fewer safety and efficacy data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/22\">",
"     22",
"    </a>",
"    ]. However, if patient adherence is a concern, valacyclovir (500 mg orally twice daily) may be preferable since twice daily dosing is more convenient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Maternal monitoring during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is generally well-tolerated and does not require clinical or laboratory monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weekly genital cultures or polymerase chain reaction (PCR) testing during late gestation are",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2,23\">",
"     2,23",
"    </a>",
"    ], as they do not predict shedding at the time of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/27\">",
"     27",
"    </a>",
"    ]. Maternal HSV is not an indication for antepartum fetal monitoring since the fetus and placenta are typically not infected.",
"   </p>",
"   <p>",
"    Transcervical procedures (eg, cerclage, chorionic villus sampling) should be avoided when genital lesions are present, but may be performed in asymptomatic patients. Transabdominal procedures (eg, amniocentesis, fetal blood sampling) are not contraindicated in women with active genital disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14710206\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major serious consequence of maternal HSV infection is transmission to the fetus during delivery. Neonatal infection results from fetal contact with virus shed from infected sites in the lower genital tract (vulva, vagina, cervix). Cesarean delivery is protective, and recommended in the setting of active genital infection (see",
"    <a class=\"local\" href=\"#H14710006\">",
"     'Evidence for cesarean delivery'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All women with a history of HSV should be asked about prodromal symptoms and examined for external lesions when they present for evaluation on the labor and delivery unit. We agree with recommendations from the Centers for Disease Control and Prevention (CDC) and ACOG that cesarean delivery should be offered as soon as possible after the onset of labor to women with a history of genital herpes and either of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2,23,28\">",
"     2,23,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active lesions (including those that have crusted)",
"     </li>",
"     <li>",
"      Prodromal symptoms (eg, pain, burning)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the membranes have been ruptured for more than six hours, it is reasonable to still perform cesarean delivery, although the benefit is not clearly proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/5\">",
"     5",
"    </a>",
"    ]. There are no data addressing if and when there is no benefit from cesarean delivery.",
"   </p>",
"   <p>",
"    If primary genital infection is acquired during the latter weeks of pregnancy, the optimal management is unclear in the absence of active genital lesions because viral shedding can be prolonged in these women",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal antibodies may not have developed before delivery. Some experts suggest cesarean delivery for all women who develop a primary clinical infection in the latter weeks of pregnancy, even if active lesions are not present, given the high risk of neonatal transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylactic cesarean delivery is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for women with recurrent HSV who have no evidence of active genital lesions at the time of delivery as the risk of neonatal HSV is very low (estimated to be",
"    <span class=\"nowrap\">",
"     2/10,000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23,29,30\">",
"     23,29,30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Cesarean delivery is also",
"    <strong>",
"     not",
"    </strong>",
"    recommended for women with active nongenital HSV lesions (eg, back, buttock, thigh) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23\">",
"     23",
"    </a>",
"    ]. These lesions should be covered with an occlusive dressing.",
"   </p>",
"   <p>",
"    Rapid HSV PCR testing to identify women with asymptomatic shedding at the time of delivery is feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/31\">",
"     31",
"    </a>",
"    ], but",
"    <strong>",
"     not",
"    </strong>",
"    recommended as the utility has not been systematically evaluated in clinical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14710006\">",
"    <span class=\"h3\">",
"     Evidence for cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protective effect of cesarean delivery against fetal transmission of HSV is supported by a prospective study of over 58,000 pregnant women in Washington state between 1982 and 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7\">",
"     7",
"    </a>",
"    ]. Among the 202 women who had HSV isolated from the cervix or external genitalia at the time of labor, 10 (5 percent) had neonates who developed HSV infection. Women with positive HSV cultures who delivered by cesarean had a marked reduction in the frequency of infected neonates compared with those who delivered vaginally",
"    <span class=\"nowrap\">",
"     (1/85",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     9/117,",
"    </span>",
"    1.2 versus 7.7 percent, odds ratio 0.14, 95% CI 0.02-1.08).",
"   </p>",
"   <p>",
"    However, as noted in this and other studies, delivery by cesarean birth does not prevent all neonatal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/5,7,19\">",
"     5,7,19",
"    </a>",
"    ]. In a national surveillance study from the CDC of 184 cases of neonatal HSV infection, 15 occurred despite cesarean delivery performed prior to membrane rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14710061\">",
"    <span class=\"h3\">",
"     Labor management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a fetal scalp electrode, which causes a break in the fetal skin, is a potential risk factor for acquisition of neonatal HSV in women with asymptomatic viral shedding. Therefore, it is prudent to limit the use of fetal scalp electrodes among women with a history of HSV infection who are in labor. External fetal heart rate monitoring is preferred as long as adequate information can be obtained.",
"   </p>",
"   <p>",
"    Avoidance of other procedures, such as vacuum or forceps delivery, is also prudent if possible since these devices can cause fetal skin abrasions and facilitate HSV infection if asymptomatic viral shedding is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14711218\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decision-making for patients with preterm premature rupture of membranes (PPROM) and active herpes simplex virus (HSV) infection requires weighing the risk of preterm delivery versus the risk of ascending in utero infection. The risks associated with prematurity will depend upon the week of gestation; the risk of fetal HSV disease will depend upon whether the woman's clinical episode is primary or recurrent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Recurrent HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study was performed to examine neonatal outcomes in 29 pregnancies complicated by both PPROM (at 25 to 31 weeks of gestation) and recurrent HSV infection that were managed expectantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/32\">",
"     32",
"    </a>",
"    ]. Expectant management consisted of hospitalization and frequent vital sign monitoring; only two women received oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for clinical symptoms. The mean gestational age at herpes lesion development after PPROM was 28.7 weeks (range 24.6 to 31.0 weeks). The mean interval from recognition of infection to delivery was 13.2 days (range 1 to 35 days). Control patients were selected who had PPROM without concomitant HSV infection. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No cases of neonatal HSV infection",
"     </li>",
"     <li>",
"      No positive neonatal HSV cultures",
"     </li>",
"     <li>",
"      Twelve infants (41 percent) had major morbidity related to prematurity and three died. Morbidity was similar for cases (PPROM with recurrent HSV) and controls (PPROM without HSV).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, the authors calculated that the maximum risk for development of a neonatal herpes infection in the setting of PPROM and recurrent genital HSV infection was 10 percent. This risk was close to the neonatal mortality rate at 26 to 27 weeks and was significantly lower than the risk of major morbidity caused by prematurity. These findings support expectant management for PPROM in the second trimester in women with active recurrent genital herpes. Above this gestational age, the risks of prematurity (which vary by gestational age) need to be balanced with the risks of in utero infection on a case-by-case basis.",
"   </p>",
"   <p>",
"    If delay of delivery is appropriate because of concerns related to gestational age remote from term, we suggest glucocorticoids for fetal lung maturation and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours) to shorten the duration of active lesions in the mother and to decrease viral burden. However, the ability of acyclovir to prevent maternal-fetal transmission has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Primary or first episode genital HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;No data are available on the risk of fetal infection during expectant management of primary or first episode genital HSV infection complicated by rupture of membranes. Optimal management remains uncertain. Confirmation of the diagnosis of primary or first episode genital nonprimary infection is desirable.",
"   </p>",
"   <p>",
"    Given the absence of data to inform decision-making, it is difficult to weigh the risks of in utero infection against the risks of preterm delivery, which vary significantly by the week of gestation. In light of the high risk of fetal transmission during primary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"     3",
"    </a>",
"    ] and the high risk of neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    in infected fetuses, some authors suggest prompt cesarean delivery of pregnancies &ge;28 weeks of gestation in an attempt to minimize the risk of fetal infection; others use a threshold of &ge;32 weeks. The neonate is then treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and surfactant.",
"   </p>",
"   <p>",
"    Before 28 (or 32) weeks, the risks of prematurity are high and may outweigh the risk of fetal infection with expectant management so",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is given to the mother to shorten the duration of lesions and reduce viral shedding; there are no data showing prevention of neonatal infection. In addition, antenatal glucocorticoids are given to reduce the morbidity and mortality related to preterm birth, if this occurs. However, it should be recognized that the majority of pregnant women with PPROM deliver within one week of membrane rupture due to premature labor or pregnancy complications (eg, abruption, chorioamnionitis), so the opportunity for further growth and maturation is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14711628\">",
"    <span class=\"h1\">",
"     POSTPARTUM AND NEONATAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parents and other caretakers with active lesions, regardless of site, should be careful when handling the infant: lesions should be covered and hands should be washed before touching the baby. Five to 15 percent of neonatal herpes is acquired after birth from a family member [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breastfeeding is not contraindicated as long as there are no herpetic breast lesions. Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      is not a contraindication to breastfeeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Communication with the pediatrician about possible neonatal herpes simplex virus (HSV) exposure is essential. Neonates with possible perinatal exposure to HSV should be monitored for clinical evidence of HSV infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link\">",
"       \"Neonatal herpes simplex virus infection: Management and prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SCREENING PREGNANT WOMEN WITH NO HSV HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, the strategies for prevention of transmission described above have not resulted in a reduction in the neonatal herpes simplex virus (HSV) rate over the past two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=see_link&amp;anchor=H21#H21\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of neonatal herpes depends on preventing acquisition of new genital HSV infection during late pregnancy and avoiding exposure of the infant to herpetic lesions during delivery. One problem has been that many women are unaware they are infected with HSV because of mild or unrecognized infections. In a national surveillance study of 184 cases of neonatal HSV infection, only 22 percent of the mothers of these neonates reported a history of genital herpes and only 9 percent had genital lesions at the time of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic screening has been proposed to identify women without HSV so they can take precautions to avoid acquiring an HSV infection and to identify women with a past history of HSV so they can be offered suppressive antiviral therapy, examined carefully for lesions at the onset of labor, and offered cesarean delivery, if indicated. Although accurate type-specific serologic tests are available to identify these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23,37,38\">",
"     23,37,38",
"    </a>",
"    ] and guide counseling, universal screening is not currently recommended by expert panels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7,21,23,39\">",
"     7,21,23,39",
"    </a>",
"    ] because available evidence indicates screening for HSV would not meet usual criteria for an effective preventive strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/40-42\">",
"     40-42",
"    </a>",
"    ], as has been demonstrated in other infections, such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a couple chooses to be screened, type-specific glycoprotein G (gG)-based assays for HSV antibodies should be specifically requested. These assays are based upon HSV-specific glycoprotein G2 for the diagnosis of HSV-2 and glycoprotein G1 for the diagnosis of HSV-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"     2",
"    </a>",
"    ]. If testing is performed, subsequent recommendations are based upon the serologic findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both partners are seronegative, no additional recommendations are made (other than monogamy).",
"     </li>",
"     <li>",
"      If the pregnant woman is seronegative for HSV-2 and the partner is seropositive, condoms should be used during intercourse in the first and second trimesters, although condoms do not provide absolute protection against transmission (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of genital herpes virus infections\", section on 'Condom use'",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"       2",
"      </a>",
"      ]. Intercourse should be avoided in the third trimester. If the woman is seronegative for HSV-1 and the partner is seropositive, both intercourse and oral-genital contact should be avoided during the third trimester. In one small study of HSV-2-seronegative pregnant women, those women whose partners were tested and found to be HSV-2 antibody-positive were more likely to report condom use than women whose partners were either HSV-2 antibody-negative or not tested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/44\">",
"       44",
"      </a>",
"      ]. Knowledge of the partner&rsquo;s HSV-1 serologic status did not affect reported sexual behavior. However, the very small number of women at risk of infection in the study and the lack of transmission or neonatal outcome data limit interpretation of the results.",
"      <br/>",
"      <br/>",
"      Another option is the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/daily)",
"      </span>",
"      to the infected male partner to prevent transmission. In a randomized trial of monogamous couples discordant for HSV-2 that did not specifically address the issue of pregnancy, valacyclovir was 48 percent effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/15\">",
"       15",
"      </a>",
"      ]. Valacyclovir would be expected to be equally effective against HSV-1, which is an increasingly common cause of neonatal HSV. However, the number of HSV-1 cases in the study was small [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/14/33001/abstract/15\">",
"       15",
"      </a>",
"      ]. Whether these data can be extrapolated to pregnancy is unknown. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link&amp;anchor=H10#H10\">",
"       \"Prevention of genital herpes virus infections\", section on 'Chronic suppressive therapy in discordant couples'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An HSV vaccine is in development. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link&amp;anchor=H19#H19\">",
"       \"Prevention of genital herpes virus infections\", section on 'Vaccine development'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the woman is HSV-2 seropositive and has a history of recurrent lesions, independent of the status of the partner, suppressive antiviral therapy for the woman may be considered beginning at 36 weeks of pregnancy to reduce the risk of active disease and shedding at onset of labor, and need for cesarean delivery (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Suppressive therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444643\">",
"    <span class=\"h1\">",
"     LINKS TO GUIDELINES FROM SELECTED NATIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/std/treatment/2010/\">",
"       Centers for Disease Control and Prevention",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.acog.org/\">",
"       American College of Obstetricians and Gynecologists",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.sogc.org/guidelines/documents/gui208CPg0806.pdf\">",
"       Society of Obstetricians and Gynaecologists of Canada",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.rcog.org.uk/womens-health/clinical-guidance/management-genital-herpes-pregnancy-green-top-30\">",
"       Royal College of Obstetricians and Gynaecologists",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/34/3618?source=see_link\">",
"       \"Patient information: Newborn conjunctivitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During pregnancy, the major complication of maternal herpes simplex virus (HSV) infection is transmission to the fetus, as neonatal infection can result in serious morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vertical transmission of HSV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classification of genital HSV infection includes: primary, first episode genital nonprimary, and recurrent infection (",
"      <a class=\"graphic graphic_table graphicRef80693 \" href=\"mobipreview.htm?9/63/10235\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification and significance of HSV infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to identify pregnant women with genital herpes by patient history alone is limited, given the high frequency of asymptomatic or minimally symptomatic infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of HSV to neonates usually occurs during labor and delivery as a result of direct contact with virus shed from infected sites (vulva, vagina, cervix, perianal area). Viral shedding can occur when maternal symptoms and lesions are absent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vertical transmission of HSV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of neonatal infection is highest in women with a primary or first episode genital HSV infection acquired near the time of delivery. This clinical observation may be related to the absence of maternal anti-HSV antibodies and to greater amount of virus shed during primary infection. Other predictors of neonatal infection in women with viral shedding during labor include invasive fetal monitoring and premature delivery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vertical transmission of HSV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      during pregnancy appears to be safe for the fetus at all stages of pregnancy. Data are more limited but reassuring regarding the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Safety of antiviral drugs in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women with primary or first episode genital nonprimary HSV, we recommend antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      400 mg orally three times daily for 7 to 10 days (treatment can be extended if healing is incomplete after 10 days). Antiviral therapy can lessen the duration of lesions and viral shedding and decrease the risk of complications in the pregnant women. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Primary or first genital infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with symptomatic infection during pregnancy, we recommend suppressive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg orally three times daily) at 36 weeks of gestation through delivery rather than no therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Suppressive therapy reduces the risk of clinical recurrence of HSV and asymptomatic viral shedding at delivery, and thus the need for cesarean delivery. However, the clinical impact on neonatal HSV is unknown. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Suppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery can decrease but not eliminate the risk of neonatal HSV infection. For women with a history of HSV and genital HSV lesions or prodromal HSV symptoms at the time of labor, we recommend cesarean delivery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14710206\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical decision-making for patients with preterm premature rupture of membranes (PPROM) and active HSV infection requires weighing the risks associated with prematurity versus the risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      HSV infection. The risks associated with prematurity depend on the week of gestation; the risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      HSV infection is difficult to estimate and depends, in part, on whether the woman's clinical episode represents primary or recurrent infection. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In women with PPROM and recurrent HSV infection, we suggest expectant management remote from term (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prescribe glucocorticoids for fetal lung maturation and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 8 hours) to shorten the duration of active lesions in the mother and to decrease viral burden. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clinical trials evaluating the optimum management of women with PPROM and primary or first episode genital nonprimary HSV infection. &nbsp;Before 28 to 32 weeks, the risks of prematurity are high and may outweigh the risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      infection with expectant management. Remote from term, we give",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      to the mother to shorten the duration of lesions and reduce viral shedding; there are no data showing prevention of neonatal infection. We also give antenatal glucocorticoids to reduce the morbidity and mortality related to preterm birth. Closer to term, immediate cesarean delivery is preferable because of the overall high risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      transmission associated with first episode genital HSV infection. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/1\">",
"      Hensleigh PA, Andrews WW, Brown Z, et al. Genital herpes during pregnancy: inability to distinguish primary and recurrent infections clinically. Obstet Gynecol 1997; 89:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/2\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/3\">",
"      Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/4\">",
"      Brown ZA, Benedetti J, Selke S, et al. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Obstet Gynecol 1996; 87:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/5\">",
"      Nahmias AJ, Josey WE, Naib ZM, et al. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 1971; 110:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/6\">",
"      Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 1987; 317:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/7\">",
"      Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/8\">",
"      Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991; 324:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/9\">",
"      Harger JH, Amortegui AJ, Meyer MP, Pazin GJ. Characteristics of recurrent genital herpes simplex infections in pregnant women. Obstet Gynecol 1989; 73:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/10\">",
"      Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/11\">",
"      Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007; 196:43.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/12\">",
"      Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA 1994; 272:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/13\">",
"      Hardy DA, Arvin AM, Yasukawa LL, et al. Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis 1990; 162:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/14\">",
"      Boggess KA, Watts DH, Hobson AC, et al. Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. Am J Obstet Gynecol 1997; 176:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/15\">",
"      Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/16\">",
"      Kimberlin DW, Baley J, Committee on infectious diseases, Committee on fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013; 131:e635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/17\">",
"      Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/18\">",
"      Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997; 99:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/19\">",
"      Stone KM, Brooks CA, Guinan ME, Alexander ER. National surveillance for neonatal herpes simplex virus infections. Sex Transm Dis 1989; 16:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/20\">",
"      Johnston C, Magaret A, Selke S, et al. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008; 198:31.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/ (Accessed on February 28, 2013).",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe, SJ. Acyclovir. In: Drugs in Pregnancy and Lactation, 8th, e-book, 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/23\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. Obstet Gynecol 2007; 109:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/24\">",
"      Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 2008; :CD004946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/25\">",
"      Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003; 188:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/26\">",
"      Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr 2012; 161:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/27\">",
"      Arvin AM, Hensleigh PA, Prober CG, et al. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med 1986; 315:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/28\">",
"      Westhoff GL, Little SE, Caughey AB. Herpes simplex virus and pregnancy: a review of the management of antenatal and peripartum herpes infections. Obstet Gynecol Surv 2011; 66:629.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Gynecological Herpes Simplex Virus Infections. ACOG Practice Bulletin No. 57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/30\">",
"      Vontver LA, Hickok DE, Brown Z, et al. Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences. Am J Obstet Gynecol 1982; 143:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/31\">",
"      Gardella C, Huang ML, Wald A, et al. Rapid polymerase chain reaction assay to detect herpes simplex virus in the genital tract of women in labor. Obstet Gynecol 2010; 115:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/32\">",
"      Major CA, Towers CV, Lewis DF, Garite TJ. Expectant management of preterm premature rupture of membranes complicated by active recurrent genital herpes. Am J Obstet Gynecol 2003; 188:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/33\">",
"      Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. Pediatr Infect Dis J 2008; 27:425.",
"     </a>",
"    </li>",
"    <li>",
"     LactMed. Acyclovir. file://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~aVoLKr:1 (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     LactMed. Valacyclovir. file://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~aVoLKr:2 (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/36\">",
"      Morris SR, Bauer HM, Samuel MC, et al. Neonatal herpes morbidity and mortality in California, 1995-2003. Sex Transm Dis 2008; 35:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/37\">",
"      Baker DA. Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol 2005; 193:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/38\">",
"      Gardella C, Krantz E, Daruthayan C, et al. The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women. Sex Transm Dis 2009; 36:211.",
"     </a>",
"    </li>",
"    <li>",
"     USPSTF guide to clinical preventive services, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/40\">",
"      Thung SF, Grobman WA. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies. Am J Obstet Gynecol 2005; 192:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/41\">",
"      Cleary KL, Par&eacute; E, Stamilio D, Macones GA. Type-specific screening for asymptomatic herpes infection in pregnancy: a decision analysis. BJOG 2005; 112:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/42\">",
"      Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000; 183:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/43\">",
"      Tita AT, Grobman WA, Rouse DJ. Antenatal herpes serologic screening: an appraisal of the evidence. Obstet Gynecol 2006; 108:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/14/33001/abstract/44\">",
"      Delaney S, Gardella C, Daruthayan C, et al. A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy. J Infect Dis 2012; 206:486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8340 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33001=[""].join("\n");
var outline_f32_14_33001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION AND SIGNIFICANCE OF HSV INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary genital infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      First episode genital nonprimary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recurrent genital infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14705932\">",
"      SEROPREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14706735\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VERTICAL TRANSMISSION OF HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Predictors of neonatal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14708541\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Safety of antiviral drugs in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14708688\">",
"      Treatment of an acute episode",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Primary or first genital infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14708874\">",
"      - Drug and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Maternal monitoring during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14710206\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14710006\">",
"      - Evidence for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14710061\">",
"      - Labor management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14711218\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Recurrent HSV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Primary or first episode genital HSV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14711628\">",
"      POSTPARTUM AND NEONATAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SCREENING PREGNANT WOMEN WITH NO HSV HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444643\">",
"      LINKS TO GUIDELINES FROM SELECTED NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/63/10235\" title=\"table 1\">",
"      Designation of genital HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/59/26556\" title=\"table 2\">",
"      HSV labor neonatal outcome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/34/3618?source=related_link\">",
"      Patient information: Newborn conjunctivitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_14_33002="Classic z-plasty";
var content_f32_14_33002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61176%7ESURG%2F71491%7ESURG%2F60824%7ESURG%2F57321%7ESURG%2F55030%7ESURG%2F74115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61176%7ESURG%2F71491%7ESURG%2F60824%7ESURG%2F57321%7ESURG%2F55030%7ESURG%2F74115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Classic Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The classic Z-plasty consists of three limbs of equal length. The angles between the central limb and each lateral limb are equal and measure 60&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Compound Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple Z-plasties are used to manage large wounds or scars not amenable to a single Z-plasty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Four flap Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A four flap Z-plasty has two additional limbs (forming A and D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Five flap Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 631px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five flap Z-plasty is a double-opposing Z-plasty with the addition of a V-Y plasty between the two (forming D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Six flap Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The six flap Z-plasty is a four flap Z-plasty with additional limbs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Double opposing Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33002=[""].join("\n");
var outline_f32_14_33002=null;
var title_f32_14_33003="Cysts in children";
var content_f32_14_33003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Renal cystic diseases in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Polycystic kidney diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autosomal recessive polycystic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autosomal dominant polycystic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cystic renal dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microcystic kidney",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic dysplasia with obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medullary cystic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephronophthisis-medullary cystic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary sponge kidney",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cortical cystic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerular cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical microcysts with interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal cysts in malformative syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Simple and multilocular renal cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        von Hippel-Lindau disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberous sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired cystic disease of the kidney",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33003=[""].join("\n");
var outline_f32_14_33003=null;
var title_f32_14_33004="Chemicals requiring specific decontamination";
var content_f32_14_33004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected chemicals requiring specific decontamination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Toxin",
"      </td>",
"      <td class=\"subtitle1\">",
"       Classification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bitumen (Tar)",
"      </td>",
"      <td>",
"       Caustic",
"      </td>",
"      <td>",
"       <p>",
"        Copious irrigation with cold water until bitumen cools and hardens.",
"       </p>",
"       <p>",
"        Bitumen that is adherent to blistered skin should be removed with blister epithelium. Bitumen adherent to unblistered skin should be covered liberally with a hydrocarbon solvent (eg, mineral oil).",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chromic acid",
"      </td>",
"      <td>",
"       Caustic with systemic toxicity",
"      </td>",
"      <td>",
"       Standard decontamination with consideration of 10 percent ascorbic acid added to irrigant.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydrofluoric acid",
"      </td>",
"      <td>",
"       Caustic with systemic toxicity",
"      </td>",
"      <td>",
"       <p>",
"        Standard decontamination followed by application of 10 percent calcium gluconate gel. Parenteral calcium administration by injection or venous or arterial infusion may be required.",
"       </p>",
"       <p>",
"        Patient at risk for hypocalcemia.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lime (calcium oxide)",
"      </td>",
"      <td>",
"       Caustic",
"      </td>",
"      <td>",
"       Brush off as much as possible prior to contact with water.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Methyl mercury",
"      </td>",
"      <td>",
"       Caustic with systemic toxicity",
"      </td>",
"      <td>",
"       Standard decontamination with blister debridement and blister fluid removal.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenol",
"      </td>",
"      <td>",
"       Caustic with systemic toxicity",
"      </td>",
"      <td>",
"       Irrigate with polyethylene glycol (PEG) 400.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phosphorus (elemental yellow phosphorus)",
"      </td>",
"      <td>",
"       Caustic",
"      </td>",
"      <td>",
"       <p>",
"        Avoid exposure to air.",
"       </p>",
"       <p>",
"        Copious water irrigation, and keep covered with water.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation",
"      </td>",
"      <td>",
"       Acute radiation syndrome",
"      </td>",
"      <td>",
"       <p>",
"        Obtain radiation monitoring device.",
"       </p>",
"       <p>",
"        Protect personnel if patient is radioactive.",
"       </p>",
"       <p>",
"        Decontaminate from periphery to center of area of exposure. Avoid creating new breaks in the skin. Allow wounds to bleed freely. Collect urine and feces for signs of internal decontamination.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reactive metals (eg, elemental sodium, potassium, lithium)",
"      </td>",
"      <td>",
"       Caustic",
"      </td>",
"      <td>",
"       Apply mineral oil and remove visible particles with forceps, gauze, or towels, then store removed particles in mineral oil.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: The treatment protocols given here are theoretically optimal, but decontamination efforts should not be delayed for a significant time to institute them.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Henretig FM (Eds). Skin Decontamination. Textbook of Pediatric Emergency Procedures, 2nd ed, Lippincott Williams &amp; Wilkins, 2008.&nbsp;Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33004=[""].join("\n");
var outline_f32_14_33004=null;
var title_f32_14_33005="Metabolic defects-methylmalonic aciduria and propionic acidemia";
var content_f32_14_33005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metabolic defects in methylmalonic aciduria and propionic acidemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 429px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PA: propionic acidemia; MMA: methylmalonic aciduria.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33005=[""].join("\n");
var outline_f32_14_33005=null;
var title_f32_14_33006="HEV serologic course";
var content_f32_14_33006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Hepatitis E virus infection typical serologic course",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. file://www.cdc.gov/hepatitis/index.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33006=[""].join("\n");
var outline_f32_14_33006=null;
var title_f32_14_33007="Anaplastic thyroid cancer CT";
var content_f32_14_33007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anaplastic thyroid cancer: CT scan of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the neck of a patient with anaplastic thyroid cancer shows diffuse infiltration of the tumor (arrow), which prevents surgical resection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James Brierley, MB, BS, MRCP, FRCR, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_14_33007=[""].join("\n");
var outline_f32_14_33007=null;
